Literature DB >> 12399426

The increased bone mass in deltaFosB transgenic mice is independent of circulating leptin levels.

M Kveiborg1, R Chiusaroli, N A Sims, M Wu, G Sabatakos, W C Horne, R Baron.   

Abstract

Transgenic mice overexpressing deltaFosB, a naturally occurring splice variant of FosB, develop an osteosclerotic phenotype. The increased bone formation has been shown to be due, at least in part, to autonomous effects of deltaFosB isoforms on cells of the osteoblast lineage. However, abdominal fat and marrow adipocytes are also markedly decreased in deltaFosB mice, leading to low serum leptin levels. Increased bone mass has been linked to the absence of leptin and leptin receptor signaling in ob/ob and db/db mice. Thus, in addition to affecting directly osteoblastogenesis and bone formation, deltaFosB isoforms might increase bone mass indirectly via a decrease in leptin. To test this hypothesis, we restored normal circulating levels of leptin in deltaFosB mice via sc implanted osmotic pumps. Complete histomorphometric analysis demonstrated that trabecular bone volume as well as dynamic parameters of bone formation was unchanged by this treatment in both deltaFosB transgenic mice and control littermates. This demonstration that restoring circulating levels of leptin in deltaFosB transgenic mice failed to rescue the bone phenotype further indicates that the marked increase in bone formation is autonomous to the osteoblast lineage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399426     DOI: 10.1210/en.2002-220420

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Energy expenditure and bone formation share a common sensitivity to AP-1 transcription in the hypothalamus.

Authors:  Glenn C Rowe; Vincent Vialou; Kazusa Sato; Hiroaki Saito; Min Yin; Thomas A Green; Sutada Lotinun; Marie Kveiborg; William C Horne; Eric J Nestler; Roland Baron
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

2.  ΔFosB Requires Galanin, but not Leptin, to Increase Bone Mass via the Hypothalamus, but both are needed to increase Energy expenditure.

Authors:  Anna Idelevich; Kazusa Sato; Kenichi Nagano; Glenn Rowe; Francesca Gori; Roland Baron
Journal:  J Bone Miner Res       Date:  2019-07-30       Impact factor: 6.741

3.  Fra-2/AP-1 controls adipocyte differentiation and survival by regulating PPARγ and hypoxia.

Authors:  J Luther; K Ubieta; N Hannemann; M Jimenez; M Garcia; C Zech; G Schett; E F Wagner; A Bozec
Journal:  Cell Death Differ       Date:  2014-01-24       Impact factor: 15.828

4.  Doubly truncated FosB isoform (Delta2DeltaFosB) induces osteosclerosis in transgenic mice and modulates expression and phosphorylation of Smads in osteoblasts independent of intrinsic AP-1 activity.

Authors:  George Sabatakos; Glenn C Rowe; Marie Kveiborg; Meilin Wu; Lynn Neff; Riccardo Chiusaroli; William M Philbrick; Roland Baron
Journal:  J Bone Miner Res       Date:  2008-05       Impact factor: 6.741

5.  Increased energy expenditure and insulin sensitivity in the high bone mass DeltaFosB transgenic mice.

Authors:  Glenn C Rowe; Cheol Soo Choi; Lynn Neff; William C Horne; Gerald I Shulman; Roland Baron
Journal:  Endocrinology       Date:  2008-09-04       Impact factor: 4.736

6.  DeltaFosB induces osteosclerosis and decreases adipogenesis by two independent cell-autonomous mechanisms.

Authors:  Marie Kveiborg; George Sabatakos; Riccardo Chiusaroli; Meilin Wu; William M Philbrick; William C Horne; Roland Baron
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production.

Authors:  Aline Bozec; Latifa Bakiri; Maria Jimenez; Thorsten Schinke; Michael Amling; Erwin F Wagner
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

8.  GosB Inhibits Triacylglycerol Synthesis and Promotes Cell Survival in Mouse Mammary Epithelial Cells.

Authors:  Gaoxiao Xu; Saixing Duan; Jianye Hou; Zhongxin Wei; Guangwei Zhao
Journal:  Biomed Res Int       Date:  2017-10-17       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.